ASCO: Daratumumab Safe in Multiple Myeloma

Results from a first-in-human trial of daratumumab indicate that the investigational drug reduced paraprotein and bone marrow plasma cells at doses greater than 4 mg/kg in patients with advanced multiple myeloma.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news